The prolonged control of mPTCL tumor progression in vivo supports the use of ATR inhibition as a single agent for the treatment of the GATA3 subgroup of PTCL. This evidence concerns the gene ATR and mature T-cell and NK-cell non-Hodgkin lymphoma.